Welcome to our dedicated page for Niagen Bioscience SEC filings (Ticker: NAGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Niagen Bioscience, Inc. (NASDAQ: NAGE) SEC filings page on Stock Titan aggregates the company’s official disclosures to the U.S. Securities and Exchange Commission, offering a structured view into how this NAD+ and healthy-aging focused bioscience business reports its operations, strategy, and governance. These documents complement the company’s press releases by providing formal detail on financial results, material agreements, equity plans, and other regulatory matters.
For investors tracking NAGE, periodic reports such as Forms 10-K and 10-Q (when available) are central references for understanding revenue drivers like Tru Niagen® consumer supplements, Niagen® ingredient sales, and pharmaceutical-grade Niagen Plus™ IV and injectable products. They also typically describe research and development priorities, intellectual property portfolios around nicotinamide riboside and other NAD+ precursors, and risk factors relevant to the company’s position in the biotechnology and dietary supplement markets.
Current reports on Form 8-K, several of which are summarized in the recent record, document specific events such as quarterly earnings announcements, share repurchase program authorizations, changes to financial outlook, material supply agreements for nicotinamide-beta-riboside chloride, and patent assignment transactions with Queen’s University Belfast. Other filings detail stockholder approvals of equity incentive plan amendments and employee stock purchase plans, which shape dilution and compensation structures.
On Stock Titan, these filings are paired with AI-powered summaries that help explain complex sections, from revenue and margin discussions to the implications of IP and supply agreements. Users can quickly scan key points in 10-K and 10-Q reports, review 8-K event disclosures, and access information relevant to insider and equity activity through forms such as Form 4 when available. Real-time updates from EDGAR ensure that new Niagen Bioscience filings appear promptly, while AI-generated highlights make it easier to interpret how each document fits into the company’s broader NAD+ science and healthy-aging strategy.
Lopez Carlos Luis reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that its SVP and General Counsel, Carlos Luis Lopez, received a grant of employee stock options covering 41,420 shares on the reported grant date. The options were awarded at no purchase price on grant and will vest in four equal annual installments on each anniversary of the grant date.
Pamir Ozan reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that its Chief Financial Officer, Pamir Ozan, received a grant of employee stock options covering 62,131 shares of common stock. The options were awarded at no cost as part of his compensation.
According to the vesting terms, one-fourth of the options will vest on each anniversary of the grant date, spreading the potential ownership benefits over four years and tying them to continued service with the company.
Fried Robert N reported acquisition or exercise transactions in this Form 4 filing.
Niagen Bioscience, Inc. reported that Chief Executive Officer Robert N. Fried received a grant of employee stock options covering 503,937 shares on the reported date. The options were granted at no cash cost to him and are held directly. One-fourth of the options vest on each anniversary of the grant date, spreading vesting over four years.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership in Niagen Bioscience Inc.
The firm reports beneficial ownership of 3,286,498 shares of Niagen Bioscience common stock, representing 4.11% of the class. It has shared voting power over 446,427 shares and shared dispositive power over 3,286,498 shares, with no sole voting or dispositive power.
The filing notes that Vanguard’s clients have the right to receive dividends and sale proceeds from these securities, and that no single client holds more than 5% of the class. Vanguard states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Niagen Bioscience.
The document also explains that, following an internal realignment on January 12, 2026, certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately on a disaggregated basis while pursuing the same investment strategies as before the realignment.
Niagen Bioscience, Inc. reported that its subsidiary ChromaDex, Inc. entered into a new assignment agreement with Queen’s University Belfast, effective December 16, 2025, replacing prior joint ownership and license arrangements. QUB assigned all of its rights in certain patent assets to ChromaDex and released the company from royalty, payment, accounting, and related obligations under the former agreements, including royalties accrued through 2025. In return, ChromaDex will make a one-time payment of approximately $1,000,000 for accrued royalties through 2024, annual payments of $500,000 and £35,000 from 2026 to 2038, and additional one-time payments of $1,500,000 in 2035 and $2,000,000 in 2038. The agreement includes customary representations, warranties, and indemnities, and the company disclosed that it issued a related press release.
Niagen Bioscience, Inc. (NAGE) reported insider share purchases by its Chief Financial Officer on a Form 4. On 11/14/2025, the CFO bought 4,464.962 shares of common stock in a direct transaction at a weighted average price of $6.81, with individual trade prices ranging from $6.7975 to $6.82. After this transaction, the CFO directly owned 7,372.159 shares of Niagen Bioscience common stock. On the same date, the CFO’s spouse acquired 2,220.443 shares at $6.85, which are reported as indirectly owned, bringing the indirect beneficial ownership to 2,220.443 shares.
Niagen Bioscience (NAGE) approved a share repurchase program authorizing up to $10.0 million of common stock. Purchases may occur in open market or privately negotiated transactions, or under a trading plan adopted in the future, in accordance with applicable securities laws.
The authorization expires on October 31, 2027 and can be modified, suspended, or terminated at any time at the Board’s discretion. The program does not obligate the company to buy any specific amount of shares.
Niagen Bioscience, Inc. furnished an 8-K announcing it issued a press release with earnings for the quarter ended September 30, 2025, and posted a corporate presentation on its website.
The press release is included as Exhibit 99.1 and the presentation as Exhibit 99.2. The information in Items 2.02 and 7.01 is being furnished and is not deemed “filed” under the Exchange Act.
Niagen Bioscience (NAGE) reported strong Q3 2025 results. Net sales were $33,986 thousand, up from $25,580 thousand a year ago. Operating income rose to $4,236 thousand and net income reached $4,578 thousand, or $0.05 diluted earnings per share. Cash and cash equivalents were $64,290 thousand as of September 30, 2025.
For the nine months, net sales were $95,584 thousand with net income of $13,250 thousand. Operating cash flow was $12,825 thousand, reflecting improved profitability and working capital. Segment mix in Q3 showed Consumer Products at $26,017 thousand and Ingredients at $7,197 thousand. As of November 3, 2025, there were 79,806,139 common shares issued and outstanding.
The company received $2,650,000 from the Elysium California settlement. In a separate Delaware matter, a final judgment awarded $9.2 million in fees and costs plus interest; the company has appealed and disclosed a reasonably possible loss of approximately $10.4 million. Trade receivables totaled $8,506 thousand, with 64.9% concentrated among three customers, and major-customer sales in the quarter included Life Extension at 11.9% and A.S. Watson Group at 10.8%.
Niagen Bioscience, Inc. disclosed in a Current Report on Form 8-K that on October 6, 2025 it issued a press release announcing an increase to its financial outlook for the full year ending December 31, 2025. The company states the press release is furnished as Exhibit 99.1 and clarifies this information is being furnished, not filed, under the Exchange Act so it is not subject to Section 18 liability and is not incorporated by reference into other filings unless expressly stated. No specific revenue, earnings, or guidance figures are included in the filing text provided.